• Mon news: Pfizer wins legal patent battle over GSK. Hospitals face hurricane-induced IV shortages. Activist investor takes $1B stake in Pfizer. MicroRNA pioneers win Nobel. Jude Bio debuts with $100M. See more on our front page

Lucentis Opportunity/Compensation??????

Dying at $1.4 billion? Move on troll

DYING with better drug Eylea from Regeneron and the biggest threat of all the diluted Avastin to boot. Just wait till Avastin comes off patent in 2019 with slew of Avastin biosimilars from small and big pharmas.

PS - The Lucentis implant project is 3 yrs behind schedule and finally reached Ph II FPI milestone in late 2015 but reported to have stopped patient enrollment due to unexpected high "complications", gasp, why in the hell would any people sign up as guinea pig of their own eyeballs?
 




I have noticed many different postings regarding this division. Any thoughts would be appreciated.

Thanks!

We have a new drug launch at the end of the year so reps from all of our franchises applied for those new positions and that opened up territories.

Great drug and though it faces a lot tough competition, it is still the best one on the market.
 












Similar threads

Replies
141
Views
38K
Replies
27
Views
7K